Hologic (HOLX) Surpasses Market Returns: Some Facts Worth Knowing

Hologic (HOLX) recently posted a daily gain of 1.46%, outperforming the S&P 500, though its monthly performance lagged the broader market. Ahead of its July 30, 2025 earnings report, consensus estimates project slight year-over-year declines for Q2 revenue and EPS, but modest full-year growth. Despite trading at a discounted forward P/E of 15.48 compared to its industry, Hologic holds a Zacks Rank of #4 (Sell) due to stagnant recent EPS estimates, reflecting a cautious outlook compounded by its Medical - Instruments industry group ranking in the bottom 28% of all Zacks industries.

Analysis

Hologic (HOLX) presents a mixed investment profile characterized by conflicting short-term performance, valuation signals, and fundamental outlooks. While the stock's recent daily gain of 1.46% outpaced the S&P 500, its one-month performance of -0.37% has lagged the broader market. Near-term headwinds are anticipated ahead of the July 30, 2025, earnings release, with consensus estimates projecting slight year-over-year declines in both revenue (-0.39% to $1.01 billion) and EPS (-0.94% to $1.05). In contrast, the full-year forecast indicates a return to modest growth, with revenue expected to rise 1.16% and EPS by 2.7%. The primary source of caution stems from stagnant analyst EPS estimates over the past month, which has resulted in a bearish Zacks Rank of #4 (Sell). This negative signal is compounded by the stock's industry context; the Medical - Instruments group ranks in the bottom 28% of all industries. On valuation, HOLX trades at a forward P/E of 15.48, a notable discount to its industry's average of 24.67. However, its PEG ratio of 2.38 is slightly above the industry average of 2.28, suggesting its price may be less attractive when factoring in its modest growth expectations.

Key Decisions for Investors

• Investors should weigh the stock's discounted forward P/E ratio against the significant negative signals, including the Zacks #4 (Sell) rating and stagnant analyst estimates, which suggest underlying business weakness.
• The upcoming earnings report on July 30, 2025, is a critical catalyst to monitor for any deviation from the expected quarterly decline or changes to the modest full-year growth outlook.
• Consider the potential for industry-wide headwinds to suppress performance, as Hologic operates within the Medical - Instruments sector, which currently ranks in the bottom 28% of over 250 industries.
• Before committing capital based on the low P/E, scrutinize the PEG ratio of 2.38, which indicates the stock may be fairly valued or even slightly expensive relative to its projected earnings growth.